1-3 of 3
Sara E Barnato, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2008) 112 (11): 4681.
https://doi.org/10.1182/blood.V112.11.4681.4681
Published: 2008
Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2008) 112 (11): 672.
https://doi.org/10.1182/blood.V112.11.672.672
Published: 2008
Journal Articles

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Sara E. Barnato, MD, Charles L. Bennett, MD PhD MPP, Kathleen Elverman, Dennis P. West, PhD, Mark Courtney, MD
Journal: Blood
Blood (2007) 110 (11): 962.
https://doi.org/10.1182/blood.V110.11.962.962
Published: 2007